Tocilizumab is more effective than adalimumab at reducing signs and symptoms of rheumatoid arthritis

Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24. The ADACTA trial, conducted in 325 patients with RA showed that tocilizumab was more effective than adalimumab for DAS28 remission (39.9% vs 10.5%, p<0.0001), low disease activity (51.5% vs. 19.8%, p<0.0001) and ACR20/50/70 responses (65.0%, 47.2%, 32.5% respectively vs. 49.4%, 27.8%, 17.9%, p<0.01). Differences between arms were also noted in favour of tocilizumab from week eight onwards in swollen and tender joint counts, erythrocyte sedimentation rate (ESR, a test that indirectly measures the among of inflammation in the body), and patient global assessment.

"Approximately one third of patients with receive biologic and this is the first head-to-head trial comparing an IL-6 inhibitor to an anti-TNF, two therapies with different modes of action," said Professor Cem Gabay from University Hospitals of Geneva, Switzerland. "This study clearly shows the benefits of tocilizumab over on various measures of rheumatoid arthritis disease activity and is the first study of its kind to determine superiority between two approved RA drugs."

The international, multicenter, randomised, double-blind, 24 week study was designed to test for treatment superiority in patients with an RA diagnosis of greater than six months who were methotrexate intolerant or for whom continued treatment with was inappropriate. Patients were randomly assigned to two arms for a total of 24 weeks: tocilizumab 8mg/kg IV every four weeks plus placebo or adalimumab 40mg subcutaneously every two weeks plus placebo. The primary endpoint of the study was mean change from baseline in DAS28 at 24 weeks.

The incidence of adverse events (AEs) was similar between groups, with 82.1% of patients having an AE in the tocilizumab arm and 82.7% in the adalimumab arm. Serious AEs and serious infections were also similar between groups (tocilizumab: 11.7%, 3.1%, adalimumab: 9.9%, 3.1%). Changes in transaminase, low-density lipoprotein (LDL) elevations, and neutrophil reductions occurred in both arms, with the proportion of patients with abnormal values higher in the tocilizumab arm. There were two deaths reported in the tocilizumab arm; one from sudden death and one from overdose.

More information: Abstract Number: LB0003

add to favorites email to friend print save as pdf

Related Stories

Gender, high DAS28-P index predictive of pain in early RA

May 18, 2012

(HealthDay) -- For patients with rheumatoid arthritis (RA), female gender and having a high proportion of disease activity score (DAS28) attributable to patient-reported components (joint tenderness and visual ...

Study confirms link between rheumatoid arthritis and COPD

May 26, 2011

Patients with rheumatoid arthritis are two times more likely to have concurrent chronic obstructive pulmonary disease (COPD) than healthy controls -- an association which was sustained even when variables such as age, gender, ...

Country economy is a stronger predictor of therapy initiation

Jun 18, 2010

There is significant disparity between 'richer' and 'poorer' countries in terms of access to biological treatments for rheumatoid arthritis (RA), according to results from a multinational study across four continents presented ...

Recommended for you

Cartilage actively contributes to arthritis

Sep 12, 2014

Melbourne researchers have discovered that cartilage plays an active role in the destruction and remodelling of joints seen in rheumatoid arthritis, rather than being an 'innocent bystander' as previously ...

Blocking one receptor could halt rheumatoid arthritis

Sep 10, 2014

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis—and ...

Motion analysis to detect arthrosis

Sep 04, 2014

Arthrosis  is excessive wear of joints beyond the usual age-related degeneration. For this reason, about 150,000 Germans are provided with an artificial knee joint every year. Early diagnosis and corresponding ...

User comments